|  |  |  |
| --- | --- | --- |
| **Day 1**  **June 4** | | |
| 8.00-9.00 | **Registration of participants** |
| **Оpening ceremony** | | |
| 9.00-9.20 | **Asilbek Khudayarov**  Minister of Health of the Republic of Uzbekistan  **Bakhodir Yusupaliev**  Chief Sanitary Doctor of the Republic of Uzbekistan  **Botir Tadjiev**  Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases  **Erkin Musabaev**  Research Institute of Virology, Association of Hepatologists of Uzbekistan  **Gulnara Aghaeva**  Association of Gastroenterology and Hepatology of Azerbaijan |
| **Session I**  **Experience in Eliminating Viral Hepatitis C. Challenges and Future Directions**  **Moderators: Laziz Tuychiev, Maria Buti** | |
| 9.20-9.35 | **Laziz Tuychiev, Uzbekistan**  Progress in Hepatitis B and C screening and treatment in Uzbekistan |
| 09.35-09.50 | **Maia Tseritelli, Georgia**  Georgia's experience in implementing the hepatitis C elimination program |
| 09.50-10.05 | **Maria Buti, Spain**  Elimination of hepatitis C in Catalonia (Spain) |
| 10.05-10.20 | **Necati Ӧrmeci, Turkiye**  Hepatitis C elimination program in Turkey |
| 10.20-10.35 | **Lubna Kamani, Pakistan**  Hepatitis C elimination program in Pakistan |
| 10.35-10.50 | **Huma Qureshi, Pakistan**  Prime Minister's Program for the HCV elimination in Pakistan |
| 10.50-11.05 | **Diana Payawal, Philippines**  Hepatitis C elimination program in the Philippines |
| 11.05-11.20 | **Heiner Wedemeyer, Germany**  Long term outcome after cure of hepatitis C (online) |
| 11.20-11.35 | **Discussion** |
| **Session II**  **Hot Topics in Hepatology. Sponsored by Abbott**  **I-Part**  **Moderator: Botir Tadjiev** | |
| 11.35-12.05 | **Raúl J. Andrade Bellido, Spain**  Early diagnosis and timely treatment: keys to improving hepatic encephalopathy prognosis (online) |
| 12.05-12.15 | Q&A session |
| 12.15-12.45 | **Grace Wong, China**  Management of NAFLD (MAFLD/MASLD) Patients Based on Disease Stage (online) |
| 12.45-12.55 | Q&A session |
| 12.55-13.00 | **IntechOpen Publishing House: Presentation on Upcoming Monograph Publication**  Elimination of Viral Hepatitis B and C: Global Initiatives, National Programs, and Scientific Advances |
| 13.00-14.00 | **Lunch** |
| **Art lecture**  **Moderators: Necati Ӧrmeci, Gulnara Aghaeva** | |
| 14.00-14.40 | **Shiv Sarin, India**  Hepatitis B Elimination: Steps to be taken (SoA) |
| **Session III**  **Hot Topics in Hepatology: Sponsored by Stada, Polisan, Inom Adviser Group, Pharm Ray**  **II-Part**  **Moderators: Elena Esaulenko, Feruza Khamrabaeva** | |
| 14.40-15.00 | **Feruza Khamrabaeva, Uzbekistan**  Importance and place of EFL application in hepatocyte cytoskeleton damage |
| 15.00-15.15 | **Elena Esaulenko, Russian Federation**  Viral hepatitis in comorbidity: Priorities in Therapy |
| 15.15-15.30 | **Visola Rakhimova, Uzbekistan**  Some pathogenetic aspects of liver cirrhosis treatment |
| 15.30-15.45 | **Kasimova Ra’no, Uzbekistan**  Malnutrition and Nutritional Recommendations in Liver Disease |
| 15.45-16.00 | **Discussion** |
| **Session IV**  **Integration of HCC Screening and Management into National Viral Hepatitis Elimination Programs**  **Moderators: Francesco Negro, Saleem Kamili** | |
| 16.00-16.15 | **Shiv Sarin, India**  Liver Cancer: Changing paradigms for screening and management |
| 16.15-16.30 | **Francesco Negro, Switzerland**  Impact of screening on liver cancer |
| 16.30 -16.45 | **Erkin Musabaev, Aziza Rakhmanova, Uzbekistan**  Two-year experience in early liver cancer screening within national viral hepatitis elimination programs in Uzbekistan: Achievements and challenges |
| 16.45-17.15 | **Discussion** |

|  |  |  |
| --- | --- | --- |
| **Day 2**  **June 5** | | |
| **Session V**  **Еxperience in organizing national programs to reduce HBV infection incidence**  **Moderators: Abdulkadir Dökmeci, Yogesh Chawla** | | |
| 9.00-9.15 | **Abdulkadir Dökmeci, Turkiye**  Hepatitis B elimination program in Turkiye |
| 9.15-9.30 | **Yogesh Chawla, India**  Hepatitis B elimination program in the India |
| 9.30-9.45 | **Kulpash Kaliaskarova, Kazakhstan**  Viral Hepatitis Elimination Program in Kazakhstan |
| 9.45-10.00 | **Elena Esaulenko, Russian Federation**  Results of the implementation of the hepatitis B elimination program in the Northwest of Russia |
| 10.00-10.15 | **Aslihan Dogdemir, Azerbaijan**  Epidemiology of viral hepatitis in Azerbaijan based on Referance Medical Group data |
| 10.15-10.30 | **Rania Tohme, USA**  Strategies for hepatitis B and hepatitis C elimination in the United States |
| 10.30-11.00 | **Discussion** |
| **Session VI**  **Experience in eliminating viral hepatitis C. Challenges and prospects.**  **II-Part**  **Moderators: Mushvig Hasanov, Rafael Esteban** | |
| 11.00-11.15 | **Mushvig Hasanov, Azerbaijan**  Gallstone disease in patients with hepatitis C virus |
| 11.15-11.30 | **Deniz Balci, Turkiye**  Current surgical management of HCC |
| 11.30-11.45 | **Rafael Esteban, Spain**  Еliminate Hepatitis C in prisons and PDW |
| 11.45-12.00 | **Elizaveta Joldasova, Uzbekistan**  Formation of a multidisciplinary systemic approach to microelimination of viral hepatitis in blood-born risk groups in Uzbekistan |
| 12.00-12.15 | **Evgeniya Kazakova, Uzbekistan**  When the Virus Doesn't Retreat: HCV Drug Resistance in a Real Case Report |
| 12.15-12.30 | **Nataliya Kan, Uzbekistan**  Diagnostic accuracy at the national scale: implementation of an external quality assessment program in the context of viral hepatitis elimination in the Republic of Uzbekistan |
| 12.30-13.00 | **Discussion** |
| 13.00-14.00 | **Lunch** |
| **Session VII**  **Hepatitis Delta session**  **Moderators: Cihan Yurdaydin, Saleem Kamili, Naranjargal Dashdorj** | |
| 14.00-14.15 | **Cihan Yurdaydin, Turkiye**  Overview of the natural history of CHD and global disparities in its management |
| 14.15-14.30 | **Bin Chen, China**  Libevitug, a first-in-class anti-preS1 monoclonal antibody, offers a novel treatment option for patients with chronic hepatitis delta infection |
| 14.30-14.45 | **Jeffrey Glenn, USA**  Lonafarnib and interferon lambda for hepatitis delta virus |
| 14.45-15.00 | **Robert Gish, USA (online)**  HDV medications: the revolution/… HDV elimination |
| 15.00-15.15 | **Naranjargal Dashdorj, Mongolia**  Screening and Diagnosing Hepatitis D Viral Infection |
| 15.15-15.30 | **Alkhazov Yusif, Azerbaijan**  Viral hepatitis Delta. Difficult patient |
| 15.30-16.00 | **Discussion** |
| 16:00-16:45 | **Panel Discussion: Expert Perspectives on**  **Innovative technologies in the treatment of delta hepatitis**  **Moderators: Bin Chen, Jeffrey Glenn** |
| **Сlosing of the conference** | |